Lupin
Lupin Limited, commonly referred to as Lupin, is a prominent global player in the pharmaceutical industry, headquartered in Mumbai, India. Founded in 1968, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Lupin is renowned for its diverse portfolio, which encompasses generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With a commitment to innovation, Lupin has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is particularly noted for its leadership in the anti-TB and cardiovascular segments, offering unique products that cater to unmet medical needs. As a result, Lupin has secured a competitive market position, consistently ranking among the top generic pharmaceutical companies globally.
DitchCarbon Score
How does Lupin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin's score of 41 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Lupin's reported carbon emissions
In 2023, Lupin Limited reported total carbon emissions of approximately 410,755,000 kg CO2e. This figure includes Scope 1 emissions of about 86,910,000 kg CO2e, Scope 2 emissions of approximately 323,845,000 kg CO2e, and significant Scope 3 emissions totalling around 854,936,000 kg CO2e. The company has shown a downward trend in emissions over the years, with total emissions decreasing from about 487,676,000 kg CO2e in 2021 to 410,755,000 kg CO2e in 2023. Lupin has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company is actively engaged in sustainability initiatives within the pharmaceuticals, biotechnology, and life sciences sector, and is based in India. While it has not set a net-zero target, it remains committed to reducing its carbon footprint and enhancing its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 103,887,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 371,883,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 680,968,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lupin is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
